Welcome to our dedicated page for Sophia Genetics Sa news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on Sophia Genetics Sa stock.
SOPHiA GENETICS SA (Nasdaq: SOPH) is a leader in the field of data-driven medicine, leveraging cutting-edge technology to advance healthcare. Based in Switzerland, the company is renowned for its high medical standards and precision. SOPHiA GENETICS has built the SOPHiA DDM™ Platform, a cloud-based SaaS platform designed to analyze complex genomic and multimodal data, delivering valuable insights for clinical and life sciences research.
Through its innovative platform, SOPHiA GENETICS supports healthcare professionals in over 100 hospitals globally, enabling them to perform faster and more accurate diagnoses using next-generation sequencing (NGS) analytics. The platform also facilitates knowledge sharing within the largest clinical genomics community.
Recently, SOPHiA GENETICS has made significant strides with several notable partnerships:
- Unilabs, a prominent European diagnostic provider, adopted the SOPHiA DDM™ Platform to enhance their HRD-status testing capabilities in solid tumors.
- Syndicate Bio in Nigeria integrated MSK-ACCESS® powered by SOPHiA DDM™, marking the first comprehensive genomic profiling and liquid biopsy availability across Africa.
- Klinikum Klagenfurt in Austria and Instituto Mário Penna in Brazil have also implemented the platform to advance their cancer diagnostics and treatment planning, particularly in blood-related cancers and disorders.
Financially, SOPHiA GENETICS is recognized for its robust operational execution and business momentum, continually reaffirming its guidance. The company is actively collaborating with tech giants like Microsoft and NVIDIA to develop a streamlined whole genome sequencing (WGS) analytical solution, promising rapid and precise insights aiding clinical decision-making.
SOPHiA GENETICS also launched SOPHiA UNITY, a global consortium to accelerate cancer research by harnessing diverse, high-quality data from leading institutions worldwide. The platform’s advanced AI-based technology and proprietary algorithms will support decision-making and expedite oncology research.
For more information, visit SOPHiAGENETICS.com or connect on LinkedIn, X, Facebook, and Instagram.
SOPHiA GENETICS (Nasdaq: SOPH) reported a robust 45% year-over-year revenue growth for Q3 2021, reaching $10.4 million. The company executed a Master Alliance Agreement with GE Healthcare to enhance oncology initiatives, expanding its market presence. Total recurring platform customers rose to 375, with a net dollar retention rate of 137%. Despite a net loss of $21.2 million or 35 cents per share, the company anticipates full-year revenue exceeding $40 million, indicating at least 41% growth for 2021.
SOPHiA GENETICS SA (Nasdaq: SOPH) has enhanced its SOPHiA DDM Universal Whole Exome platform with the integration of Agilent's SureSelect Human All Exon v8. This new bioinformatic workflow streamlines analysis from sample to variant report, supporting both germline and cancer applications. Key features include reduced turnaround time, multiple variant detection, tailored analytics for Agilent data, and a comprehensive gene coverage. The solution aims to accelerate research in rare and inherited diseases, making data-driven medicine more accessible.
SOPHiA GENETICS (Nasdaq: SOPH) announced its participation in several upcoming investor conferences, including the Credit Suisse 30th Annual Healthcare Conference on November 11, the Piper Sandler 33rd Annual Healthcare Conference starting November 22, and the Evercore ISI HealthCONx Conference on November 30. Investors can access live and archived presentations through the company's Investors section on their website. SOPHiA GENETICS focuses on data-driven medicine, utilizing its cloud-based SOPHiA DDM™ Platform in over 780 institutions worldwide.
SOPHiA GENETICS (Nasdaq: SOPH) announced it will report Q3 financial results on November 10, 2021, before the market opens. Management will host a webcast at 8:30 a.m. ET to discuss results, business advancements, and future outlook. The SOPHiA DDM™ Platform, their cloud-based SaaS solution, is utilized by over 780 institutions globally, aiming to set data-driven medicine as a standard. The live audio will be available on the company’s Investors section of the website, with an archived replay afterwards.
SOPHiA GENETICS (Nasdaq: SOPH) has launched the SOPHiA Clinical Exome Solution v3, which enhances probe design and detection capabilities for investigating Mendelian diseases. This application combines a capture-based target enrichment kit with the SOPHiA DDM™ platform, achieving over 90% analytical sensitivity for CNV detection. Enhanced probe design allows for improved detection of rare disorders across the mitochondrial genome and 280 known disorder-causing genomic locations. This innovation aims to streamline data analysis and improve institutional resource efficiency.
SOPHiA GENETICS (NASDAQ: SOPH) reported Q2 2021 revenue of $10.2 million, a 72% increase Year-over-Year (YoY). The customer base grew to 780. The company raised approximately $217 million from its IPO and $20 million from a private placement. Q2 gross profit was $6.2 million, with a margin of 61%, down from 67% in Q2 2020. Operating expenses rose to $22.2 million, leading to a net loss of $18.4 million. For 2021, revenue guidance exceeds $39 million, projecting over 37% growth.
SOPHiA GENETICS (Nasdaq: SOPH) announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021. The presentation is scheduled for 9:30 a.m. Eastern Time/3:30 p.m. Central European Time and will be accessible via a live and archived webcast on the company’s website.
The company is a leader in data-driven medicine and offers the SOPHiA DDM™ Platform, which supports over 780 institutions globally in analyzing complex data sets for healthcare and life sciences.
SOPHiA GENETICS (Nasdaq: SOPH) will release its second quarter 2021 financial results on September 9, 2021, before market open. The management will host a conference call at 8:30 a.m. ET to discuss these results, alongside business developments and future outlook. The company focuses on data-driven medicine and operates the SOPHiA DDM™ Platform, utilized by over 780 institutions globally. A live webcast of the call will be accessible in the 'Investors' section of their website, with an archived replay available post-event.
SOPHiA GENETICS (Nasdaq: SOPH) announced that it will release its financial results for Q2 2021 on September 9, 2021, before market opening. A conference call will follow at 8:30 a.m. ET to discuss these results, business developments, and future outlook. The company emphasizes its commitment to data-driven medicine through its SOPHiA DDM™ Platform, utilized by over 780 healthcare institutions globally, reinforcing its strategic position in the healthcare technology landscape.
Dasa, Brazil's largest healthcare network, is expanding its partnership with SOPHiA GENETICS SA (Nasdaq: SOPH) to launch the first decentralized HRD analytics solution in Latin America. This solution focuses on identifying cancer patients who may benefit from PARP inhibitors, promoting personalized therapies. With over 20 million patient interactions yearly, Dasa enhances its genomic capabilities using SOPHiA's platform, built on a collaboration that started in 2016. This innovation aims to improve patient outcomes through efficient data management and tailored treatment strategies.
FAQ
What is the current stock price of Sophia Genetics Sa (SOPH)?
What is the market cap of Sophia Genetics Sa (SOPH)?
What does SOPHiA GENETICS do?
What is the SOPHiA DDM™ Platform?
Where is SOPHiA GENETICS based?
Who are some of SOPHiA GENETICS' partners?
What is SOPHiA UNITY?
How does SOPHiA GENETICS support precision medicine?
What recent advancements have SOPHiA GENETICS made?
What is the company's mission?
How does SOPHiA GENETICS ensure data privacy and quality?
How can I learn more about SOPHiA GENETICS?
